ILTOO PHARMA
Desconocido
ARTiDe: Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe)
ILTOO PHARMA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2022-DISEASE-06-two-stage
Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, a...
2023-04-27 - 2028-06-30 | Financiado
2023-04-27 - 2028-06-30 | Financiado
MOODSTRATIFICATION: Immune Signatures for Therapy Stratification in Major Mood Disorders
ILTOO PHARMA
participó en un
H2020:
H2020-SC1-2016-2017
Objective: MOODSTRATIFICATION brings together 11 partners (psychiatrists, immunologists, epidemiologists, industry) from 7 countries stratif...
2017-12-05 - 2023-06-30 | Financiado
2017-12-05 - 2023-06-30 | Financiado
DIABIL-2: Ultra low dose of IL 2 for the treatment of recently diagnosed type 1 diabetes
ILTOO PHARMA
participó en un
FP7:
Concept
The discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the fai...
Financiado
Financiado
* No se disponen de datos de la empresa actual.